Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
SCRI Development Innovations, LLC
With
Aventis Pharmaceuticals
Upon determination of eligibility, patients will receive:
Neoadjuvant Docetaxel + Doxorubicin + Cyclophosphamide + Surgery
Adjuvant patients will enter the study after surgery and receive Docetaxel+ Doxorubicin + Cyclophosphamide. Patients treated with lumpectomy will undergo postoperative radiation therapy after completion of chemotherapy. Patients with positive estrogen and/or progesterone receptors will begin anti-estrogen therapy after the last course of chemotherapy.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
To be included in this study, you must meet the following criteria:
Histologically proven breast cancer
Females, age greater than 18 years
Ability to perform activites of daily living with minimal assistance
Normal cardiac function
Adequate bone marrow, liver and kidney
Signed informed consent prior to beginning specific protocol procedures
You may not be if
You cannot participate in this study if any of the following apply to you:
Prior systemic anticancer therapy for breast cancer
Prior anthracycline or taxane based chemotherapy for any malignancy
Pregnant or breast-feeding women.
Pre-existing moderate to severe motor or sensory neurotoxicity
Other serious illness or medical condition
Clareo Health | Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer
